Literature DB >> 32467344

A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Alisa M Goldstein1, Elizabeth M Gillanders1, Melissa Rotunno2, Rolando Barajas1, Mindy Clyne1, Elise Hoover1, Naoko I Simonds3, Tram Kim Lam1, Leah E Mechanic1.   

Abstract

The application of next-generation sequencing (NGS) technologies in cancer research has accelerated the discovery of somatic mutations; however, progress in the identification of germline variation associated with cancer risk is less clear. We conducted a systematic literature review of cancer genetic susceptibility studies that used NGS technologies at an exome/genome-wide scale to obtain a fuller understanding of the research landscape to date and to inform future studies. The variability across studies on methodologies and reporting was considerable. Most studies sequenced few high-risk (mainly European) families, used a candidate analysis approach, and identified potential cancer-related germline variants or genes in a small fraction of the sequenced cancer cases. This review highlights the importance of establishing consensus on standards for the application and reporting of variants filtering strategies. It also describes the progress in the identification of cancer-related germline variation to date. These findings point to the untapped potential in conducting studies with appropriately sized and racially diverse families and populations, combining results across studies and expanding beyond a candidate analysis approach to advance the discovery of genetic variation that accounts for the unexplained cancer heritability. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32467344      PMCID: PMC8279039          DOI: 10.1158/1055-9965.EPI-19-1551

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  227 in total

1.  Germline mutations causing familial lung cancer.

Authors:  Koichi Tomoshige; Keitaro Matsumoto; Tomoshi Tsuchiya; Masahiro Oikawa; Takuro Miyazaki; Naoya Yamasaki; Hiroyuki Mishima; Akira Kinoshita; Toru Kubo; Kiyoyasu Fukushima; Koh-Ichiro Yoshiura; Takeshi Nagayasu
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

2.  A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.

Authors:  Sohela Shah; Kasmintan A Schrader; Esmé Waanders; Andrew E Timms; Joseph Vijai; Cornelius Miething; John T Sandlund; Marshall S Horwitz; Charles G Mullighan; Kenneth Offit; Jeremy Wechsler; Jun Yang; James Hayes; Robert J Klein; Jinghui Zhang; Lei Wei; Gang Wu; Michael Rusch; Panduka Nagahawatte; Jing Ma; Shann-Ching Chen; Guangchun Song; Jinjun Cheng; Paul Meyers; Deepa Bhojwani; Suresh Jhanwar; Peter Maslak; Martin Fleisher; Jason Littman; Lily Offit; Rohini Rau-Murthy; Megan Harlan Fleischut; Marina Corines; Rajmohan Murali; Xiaoni Gao; Christopher Manschreck; Thomas Kitzing; Vundavalli V Murty; Susana Raimondi; Roland P Kuiper; Annet Simons; Joshua D Schiffman; Kenan Onel; Sharon E Plon; David Wheeler; Deborah Ritter; David S Ziegler; Kathy Tucker; Rosemary Sutton; Georgia Chenevix-Trench; Jun Li; David G Huntsman; Samantha Hansford; Janine Senz; Thomas Walsh; Ming Lee; Christopher N Hahn; Kathryn Roberts; Mary-Claire King; Sarah M Lo; Ross L Levine; Agnes Viale; Nicholas D Socci; Katherine L Nathanson; Hamish S Scott; Mark Daly; Steven M Lipkin; Scott W Lowe; James R Downing; David Altshuler
Journal:  Nat Genet       Date:  2013-09-08       Impact factor: 38.330

3.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.

Authors:  Iñaki Comino-Méndez; Francisco J Gracia-Aznárez; Francesca Schiavi; Iñigo Landa; Luis J Leandro-García; Rocío Letón; Emiliano Honrado; Rocío Ramos-Medina; Daniela Caronia; Guillermo Pita; Alvaro Gómez-Graña; Aguirre A de Cubas; Lucía Inglada-Pérez; Agnieszka Maliszewska; Elisa Taschin; Sara Bobisse; Giuseppe Pica; Paola Loli; Rafael Hernández-Lavado; José A Díaz; Mercedes Gómez-Morales; Anna González-Neira; Giovanna Roncador; Cristina Rodríguez-Antona; Javier Benítez; Massimo Mannelli; Giuseppe Opocher; Mercedes Robledo; Alberto Cascón
Journal:  Nat Genet       Date:  2011-06-19       Impact factor: 38.330

4.  Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.

Authors:  Jianxin Shi; Xiaohong R Yang; Bari Ballew; Melissa Rotunno; Donato Calista; Maria Concetta Fargnoli; Paola Ghiorzo; Brigitte Bressac-de Paillerets; Eduardo Nagore; Marie Francoise Avril; Neil E Caporaso; Mary L McMaster; Michael Cullen; Zhaoming Wang; Xijun Zhang; William Bruno; Lorenza Pastorino; Paola Queirolo; Jose Banuls-Roca; Zaida Garcia-Casado; Amaury Vaysse; Hamida Mohamdi; Yasser Riazalhosseini; Mario Foglio; Fanélie Jouenne; Xing Hua; Paula L Hyland; Jinhu Yin; Haritha Vallabhaneni; Weihang Chai; Paola Minghetti; Cristina Pellegrini; Sarangan Ravichandran; Alexander Eggermont; Mark Lathrop; Ketty Peris; Giovanna Bianchi Scarra; Giorgio Landi; Sharon A Savage; Joshua N Sampson; Ji He; Meredith Yeager; Lynn R Goldin; Florence Demenais; Stephen J Chanock; Margaret A Tucker; Alisa M Goldstein; Yie Liu; Maria Teresa Landi
Journal:  Nat Genet       Date:  2014-03-30       Impact factor: 38.330

5.  Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs.

Authors:  Yoji Kukita; Jiro Okami; Noriko Yoneda-Kato; Ikuko Nakamae; Takeshi Kawabata; Masahiko Higashiyama; Junya Kato; Ken Kodama; Kikuya Kato
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

6.  Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?

Authors:  Tú Nguyen-Dumont; Zhi L Teo; Fleur Hammet; Alexis Roberge; Maryam Mahmoodi; Helen Tsimiklis; Daniel J Park; Bernard J Pope; Andrew Lonie; Miroslav K Kapuscinski; Khalid Mahmood; David E Goldgar; Graham G Giles; Ingrid Winship; John L Hopper; Melissa C Southey
Journal:  BMC Cancer       Date:  2018-02-08       Impact factor: 4.430

7.  Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

Authors:  Eleanor Fewings; Alexey Larionov; James Redman; Mae A Goldgraben; James Scarth; Susan Richardson; Carole Brewer; Rosemarie Davidson; Ian Ellis; D Gareth Evans; Dorothy Halliday; Louise Izatt; Peter Marks; Vivienne McConnell; Louis Verbist; Rebecca Mayes; Graeme R Clark; James Hadfield; Suet-Feung Chin; Manuel R Teixeira; Olivier T Giger; Richard Hardwick; Massimiliano di Pietro; Maria O'Donovan; Paul Pharoah; Carlos Caldas; Rebecca C Fitzgerald; Marc Tischkowitz
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-04-27

8.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

9.  Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas.

Authors:  Miriam J Smith; James O'Sullivan; Sanjeev S Bhaskar; Kristen D Hadfield; Gemma Poke; John Caird; Saba Sharif; Diana Eccles; David Fitzpatrick; Daniel Rawluk; Daniel du Plessis; William G Newman; D Gareth Evans
Journal:  Nat Genet       Date:  2013-02-03       Impact factor: 38.330

10.  Whole Exome Sequencing of Chronic Myeloid Leukemia Patients.

Authors:  Shaghayegh Sabri; Manouchehr Keyhani; Mohammad Taghi Akbari
Journal:  Iran J Public Health       Date:  2016-03       Impact factor: 1.429

View more
  3 in total

1.  Exome-Wide Pan-Cancer Analysis of Germline Variants in 8,719 Individuals Finds Little Evidence of Rare Variant Associations.

Authors:  Zoe Guan; Ronglai Shen; Colin B Begg
Journal:  Hum Hered       Date:  2021-10-29       Impact factor: 0.444

Review 2.  Opportunities for Gene and Environment Research in Cancer: An Updated Review of NCI's Extramural Grant Portfolio.

Authors:  Armen A Ghazarian; Naoko Ishibe Simonds; Gabriel Y Lai; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-12-15       Impact factor: 4.090

3.  The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.

Authors:  Jean-Noël Hubert; Voreak Suybeng; Maxime Vallée; Tiffany M Delhomme; Eve Maubec; Anne Boland; Delphine Bacq; Jean-François Deleuze; Fanélie Jouenne; Paul Brennan; James D McKay; Marie-Françoise Avril; Brigitte Bressac-de Paillerets; Estelle Chanudet
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.